ARVN FY 2024 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$263M+235.5% YoY

Gross Profit

$263M100.0% margin

Operating Income

-$250M-95.0% margin

Net Income

-$199M-75.5% margin

EPS (Diluted)

$-2.77

Cash Flow

Operating Cash Flow

-$259M

Free Cash Flow

-$261M

Stock-Based Comp.

$88M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$530M

Stockholders' Equity

$562M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$263M	$79M	+235.5%
Gross Profit	$263M	$79M	+235.5%
Operating Income	-$250M	-$402M	+37.7%
Net Income	-$199M	-$367M	+45.8%